Wockhardt Limited
WOCKPHARMA
Κατάταξη σε μετοχές
#4493
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical... Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Τιμή μετοχής
$21.04
Τελευταίος συγχρονισμός: 2026-10-19
Κεφαλαιοποίηση
$3.42B
Αλλαγή (1 ημέρα)
-2.39%
Αλλαγή (1 έτος)
38.07%
Χώρα
IN
Εμπόριο Wockhardt Limited (WOCKPHARMA)
Κατηγορία
Healthcare
EPS για Wockhardt Limited (WOCKPHARMA)
EPS στις June 2026 TTM: $0.28
Σύμφωνα με τις τελευταίες οικονομικές αναφορές και την τιμή της μετοχής της Wockhardt Limited, το τρέχον EPS της εταιρείας (TTM) είναι $0.28. Στο τέλος του 2024, η εταιρεία είχε EPS $-0.39, μείωση σε σύγκριση με το EPS του 2023 που ήταν $-0.47.
Ιστορικό EPS της Wockhardt Limited από 2004 έως 2026
EPS στο τέλος κάθε έτους
| Έτος | EPS | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $0.28 | -794.25% |
| 2025 | $-0.04 | -90.88% |
| 2024 | $-0.39 | -18.45% |
| 2023 | $-0.47 | 77.08% |
| 2022 | $-0.27 | -21.59% |
| 2021 | $-0.34 | 73.20% |
| 2020 | $-0.20 | -47.92% |
| 2019 | $-0.38 | -55.39% |
| 2018 | $-0.84 | 209.37% |
| 2017 | $-0.27 | -179.67% |
| 2016 | $0.34 | -41.89% |
| 2015 | $0.59 | -53.86% |
| 2014 | $1.28 | -51.83% |
| 2013 | $2.65 | 366.49% |
| 2012 | $0.57 | 232.75% |
| 2011 | $0.17 | -109.11% |
| 2010 | $-1.88 | 678.46% |
| 2008 | $-0.24 | -129.20% |
| 2007 | $0.83 | 80.04% |
| 2006 | $0.46 | -4.80% |
| 2005 | $0.48 | 16.08% |
| 2004 | $0.41 | 0.00% |
EPS για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | EPS | Διαφορά EPS | Χώρα |
|---|---|---|---|
| $2.41 | 767.84% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $0.02 | -93.23% |
HK
|
